Literature DB >> 18941434

Gastrointestinal complications of oncologic therapy.

Marta Davila1, Robert S Bresalier.   

Abstract

Gastrointestinal complications are common in patients undergoing various forms of cancer treatment, including chemotherapy, radiation therapy, and molecular-targeted therapies. Many of these complications are life-threatening and require prompt diagnosis and treatment. Complications of oncologic therapy can occur in the esophagus (esophagitis, strictures, bacterial, viral and fungal infections), upper gastrointestinal tract (mucositis, bleeding, nausea and vomiting), colon (diarrhea, graft-versus-host disease, colitis and constipation), liver (drug hepatotoxicity and graft-versus-host disease), and pancreas (pancreatitis). Treatment of the different gastrointestinal complications should be tailored to the individual patient and based on the underlying pathophysiology of the complication.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18941434     DOI: 10.1038/ncpgasthep1277

Source DB:  PubMed          Journal:  Nat Clin Pract Gastroenterol Hepatol        ISSN: 1743-4378


  13 in total

Review 1.  Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer.

Authors:  Anna E Kersh; Spencer Ng; Yun Min Chang; Maiko Sasaki; Susan N Thomas; Haydn T Kissick; Gregory B Lesinski; Ragini R Kudchadkar; Edmund K Waller; Brian P Pollack
Journal:  J Clin Pharmacol       Date:  2017-11-14       Impact factor: 3.126

2.  Clinically defined chemotherapy-associated bowel syndrome predicts severe complications and death in cancer patients.

Authors:  Maria J G T Vehreschild; Arne M K Meissner; Oliver Andreas Cornely; Georg Maschmeyer; Silke Neumann; Marie von Lilienfeld-Toal; Meinholf Karthaus; Mohammed Wattad; Peter Staib; Martin Hellmich; Hildegard Christ; Jörg Janne Vehreschild
Journal:  Haematologica       Date:  2011-08-22       Impact factor: 9.941

3.  The Superoxide Dismutase Mimetic M40403, Improves 5-Fluorouracil-induced Small Intestinal Mucositis in a Mouse Model.

Authors:  Sung Kyun Yim; Kyoung Min Kim; Chang-Hoon Lee; Eun-Kee Song; Seung Ok Lee; Sang Wook Kim; In Hee Kim; Seong-Hun Kim; Seung Young Seo; Soo Teik Lee
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

4.  Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management.

Authors:  Alexander Stein; Wieland Voigt; Karin Jordan
Journal:  Ther Adv Med Oncol       Date:  2010-01       Impact factor: 8.168

Review 5.  Management of Mucositis During Chemotherapy: From Pathophysiology to Pragmatic Therapeutics.

Authors:  Ysabella Z A Van Sebille; Romany Stansborough; Hannah R Wardill; Emma Bateman; Rachel J Gibson; Dorothy M Keefe
Journal:  Curr Oncol Rep       Date:  2015-11       Impact factor: 5.075

6.  Chemotherapy-Induced Ischemic Colitis in a Patient with Jejunal Lymphoma.

Authors:  Ulrich Halm; Stephan Sack; Markus Zachäus
Journal:  Case Rep Gastroenterol       Date:  2010-10-21

7.  Esophagitis and its causes: Who is "guilty" when acid is found "not guilty"?

Authors:  Laurino Grossi; Antonio Francesco Ciccaglione; Leonardo Marzio
Journal:  World J Gastroenterol       Date:  2017-05-07       Impact factor: 5.742

8.  Consumption of Lactose, Other FODMAPs and Diarrhoea during Adjuvant 5-Fluorouracil Chemotherapy for Colorectal Cancer.

Authors:  Reetta Holma; Reijo Laatikainen; Helena Orell; Heikki Joensuu; Katri Peuhkuri; Tuija Poussa; Riitta Korpela; Pia Österlund
Journal:  Nutrients       Date:  2020-02-04       Impact factor: 5.717

9.  Diarrhea in neutropenic children with cancer: An Egyptian center experience, with emphasis on neutropenic enterocolitis.

Authors:  Laila M Sherief; Mohamed R Beshir; Naglaa Mohamed Kamal; Maha K Gohar; Ghada K Gohar
Journal:  Indian J Med Paediatr Oncol       Date:  2012-04

10.  Chimonanthus nitens var. salicifolius Aqueous Extract Protects against 5-Fluorouracil Induced Gastrointestinal Mucositis in a Mouse Model.

Authors:  Zhenze Liu; Jun Xi; Sven Schröder; Weigang Wang; Tianpei Xie; Zhugang Wang; Shisan Bao; Jian Fei
Journal:  Evid Based Complement Alternat Med       Date:  2013-12-03       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.